A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. [electronic resource]
Producer: 20110419Description: 750-5 p. digitalISSN:- 1532-1827
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Dacarbazine -- administration & dosage
- Drug Administration Schedule
- Female
- Humans
- Male
- Maximum Tolerated Dose
- Melanoma -- drug therapy
- Middle Aged
- Neoplasms -- drug therapy
- Neutropenia -- chemically induced
- Phthalazines -- administration & dosage
- Piperazines -- administration & dosage
- Poly(ADP-ribose) Polymerase Inhibitors
- Thrombocytopenia -- chemically induced
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.